Workflow
Immunome, Inc. (IMNM) Reports Q2 Loss, Misses Revenue Estimates
IMNMImmunome(IMNM) ZACKS·2024-08-12 22:15

Company Performance - Immunome, Inc. reported a quarterly loss of 0.49pershare,whichwasworsethantheZacksConsensusEstimateofalossof0.49 per share, which was worse than the Zacks Consensus Estimate of a loss of 0.38, and compared to a loss of 0.46pershareayearago,indicatinganearningssurpriseof−28.950.46 per share a year ago, indicating an earnings surprise of -28.95% [1] - The company posted revenues of 2.36 million for the quarter ended June 2024, missing the Zacks Consensus Estimate by 9.77%, and down from 4.26millioninthesamequarterlastyear[2]−Overthelastfourquarters,ImmunomehassurpassedconsensusEPSestimatesonlyonceandhastoppedconsensusrevenueestimatesjustonce[2]StockOutlook−Immunomeshareshaveincreasedapproximately20.84.26 million in the same quarter last year [2] - Over the last four quarters, Immunome has surpassed consensus EPS estimates only once and has topped consensus revenue estimates just once [2] Stock Outlook - Immunome shares have increased approximately 20.8% since the beginning of the year, outperforming the S&P 500's gain of 12% [3] - The current consensus EPS estimate for the upcoming quarter is -0.42 on revenues of 2.63million,andforthecurrentfiscalyear,itis−2.63 million, and for the current fiscal year, it is -3.66 on revenues of $5.55 million [7] - The estimate revisions trend for Immunome is mixed, resulting in a Zacks Rank 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Immunome belongs, is currently in the top 30% of over 250 Zacks industries, suggesting a favorable outlook for stocks within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor sentiment and stock performance [5]